Purpose: To assess the effect of incision width (5.0 and 3.2 mm) on graft survival and endothelial cell loss 6 months and 1 year after Descemet stripping automated endothelial keratoplasty (DSAEK).
D escemet stripping automated endothelial keratoplasty (DSAEK) has become a preferred surgical treatment for corneal endothelial decompensation because it provides rapid visual recovery, uses a smaller wound size, minimizes induced astigmatism, and, most importantly, better maintains globe integrity than penetrating keratoplasty (PKP). 1 However, because DSAEK is a relatively new procedure, little is known about the operative parameters that influence long-term graft survival and endothelial cell loss with DSAEK and how these parameters of performance compare with PKP.
We recently conducted a prospective study of DSAEK to assess graft survival and endothelial cell loss in comparison with a subset of patients from the Cornea Donor Study (CDS) and its ancillary study, the Specular Microscopy Ancillary Study (SMAS), 2,3 employing the same donor and recipient inclusion/exclusion criteria and follow-up examination procedures and using the same specular microscopy reading center for determination of the central endothelial cell density (ECD). 3, 4 The 1-year endothelial cell loss in the DSAEK eyes significantly exceeded that in SMAS PKP eyes (38% vs 20%; P , 0.001).
Two sites participated in this study, with the principal variation in surgical technique being the incision width used for graft insertion (3.2 vs 5.0 mm). A previous ex vivo study on donor eyes examining different methods of corneal graft delivery suggested that incision width has a significant effect on endothelial cell loss. 4 This study from the same DSAEK data set 5 examined whether the difference in incision width had a significant effect on 1-year graft survival and endothelial cell loss.
METHODS
In this retrospective interventional study, subjects were treated with DSAEK at Gorovoy Eye Specialists (Fort Myers, FL) or Price Vision Group (Indianapolis, IN) between June 2006 and September 2007. The University Hospitals Case Medical Center (Cleveland, OH) Institutional Review Board approved the study. Each subject provided written informed consent to participate.
As in the CDS, eligible subjects had conditions of moderate risk for graft failure from endothelial decompensation (principally Fuchs dystrophy or pseudophakic corneal edema). 2, 3 Patients undergoing a regraft or with 2 or more quadrants of stromal neovascularization, uncontrolled uveitis, uncontrolled glaucoma, previous placement of a glaucoma shunt, or fellow eye visual acuity , 20/200 were excluded. Only 1 eye per patient was included in the study. Eligible donor corneas were from 10 to 75 years old, with an eye bank-measured central ECD of 2300-3300 cells per square millimeter, death-to-surgery time of # 5 days, and death-topreservation time of # 12 hours, if the body was refrigerated or eyes were iced, and # 8 hours, if not. These donor eligibility criteria were the same as those used in the SMAS. 2, 3, 6 The Case Vision Research Coordinating Center (VRCC) developed data collection forms that paralleled those used in the CDS and the SMAS, provided them to participating eye banks and clinical sites, collected and analyzed the data, and audited both clinical sites during and at conclusion of the follow-up period to verify all data. 2, 3, 7 Surgical Technique Two experienced surgeons (F.W.P. and M.G.) performed the DSAEK procedures, as previously described. 8, 9 If a cataract was present, a phacoemulsification procedure was performed before DSAEK; this had the added benefit of creating more space in the anterior chamber to safely position the graft. Patients with anterior chamber intraocular lenses were not included in this study.
The donor cornea was dissected with a microkeratome and associated artificial anterior chamber (model CB; Moria, Doylestown, PA). The artificial anterior chamber was pressurized with air when the 3.2-mm incision was used and with balanced salt solution when the 5.0-mm incision was used. The donor cornea was transferred to a punching system and cut with a trephine, with a diameter of 8.25-9.0 mm. Surgery was performed on the recipient with topical anesthesia and monitored intravenous sedation. A 3.2-mm clear corneal temporal incision at one site or a 5-mm clear corneal or scleral tunnel temporal incision at the other site was made, and Descemet membrane and endothelium were stripped from within the planned graft area. The donor cornea was folded into a ''taco'' configuration, with a drop of cohesive sodium hyaluronate viscoelastic on the inside to protect the endothelium, and inserted into the anterior chamber using single-point fixation forceps (both surgeons used Goosey and Ogawa forceps; Moria, Antony, France). The graft was unfolded, and air was injected into the anterior chamber posterior to the graft. Three or 4 small equally spaced incisions were placed anteriorly in the midperipheral recipient cornea down to the graft interface to help drain any entrapped fluid.
When the 3.2-mm incision was used, the anterior chamber was completely filled with air for 1 hour followed by partial air removal at the slit lamp before discharging the patient. When the 5-mm incision size was used, the anterior chamber was completely filled with air for 8 minutes, most of the air was removed and replaced with balanced salt solution, a drop of homatropine 5% was instilled to prevent pupillary block, tobramycin/dexamethasone ointment was placed in the eye, and the patient was discharged after remaining face up for 30 minutes in the recovery room to allow the remaining small air bubble to press the graft against the recipient cornea.
Specular Microscopy and ECD Determination
Participating eye banks that provided donor corneas eligible for the study included Central Florida Lions Eye and Tissue Bank (Tampa, FL), Indiana Lions Eye and Tissue Transplant Bank (Indianapolis, IN), North Carolina Eye Bank (Winston-Salem, NC), Heartland Lions Eye Bank (St. Louis, MO), and SightLife (Seattle, WA); each had previously participated in the SMAS and were familiar with image capture and transmission procedures. 3, 7, 10 As in the SMAS, after their specular microscopes had been again calibrated by the Case Specular Microscopy Reading Center (SMRC), the eye banks electronically submitted a single image of the central endothelium of each study donor cornea to the SMRC for ECD determination. 3, 7, 10 After SMRC calibration of the clinical specular microscope (Konan Medical, Corp, Torrance, CA) or confocal microscope (Nidek, Inc, Fremont, CA) at each site, 3 postoperative images of the central corneal graft endothelium were captured at the 6-month (range 5-7 months) and 12-month (range 9-15 months) study examinations and transmitted to the SMRC for analysis. SMRC analysis procedures for donor and postoperative images were as previously described. 3, 7, 10 
Statistical Methods
Endothelial cell loss was calculated for each subject by subtracting postoperative ECD from baseline ECD, dividing by baseline ECD, and multiplying by 100. As in the SMAS, if the donor image could not be analyzed by the SMRC or was unavailable, the eye bank-determined ECD was used. All postoperative ECD data were derived from SMRC-determined ECD-analyzed images. For normally distributed variables, descriptive statistics were reported as mean 6 SD and compared using a 2-sample Student t test. Otherwise, they were reported as median (25th and 75th quartile) and compared using the Wilcoxon rank sum test or they were expressed as a proportion and compared using x 2 analysis or Fisher exact test, as appropriate. All reported P values were 2 sided, and P values , 0.05 were considered significant. All statistical analyses were performed with SAS software (version 9.1; SAS Institute, Cary, NC).
RESULTS

Sample Size
A total of 175 subjects were originally enrolled in the study comparing a prospective series of DSAEK cases to a subgroup of the SMAS. 5 For the purpose of this study, 8 cases were excluded: (1) One eye was the fellow eye of a previously enrolled study subject; (2) One subject received a DSAEK to treat a previously failed DSAEK; and (3) In 6 eyes, the graft was inserted with a funnel glide. Thus, 167 eyes (167 subjects) were available for this retrospective analysis of folded graft insertion with forceps through different incision widths. Of the 167 DSAEK eyes, 134 (80%) were examined and found to have clear grafts at 1 year, 19 (11%) had clear grafts at 6 months and returned to their referring doctors, 6 (4%) were lost to follow-up before the 6-month examination, 3 (1.8%) died, 1 (0.59%) withdrew, and 4 (2.4%) experienced a graft failure within the first 15 months. Of the 134 DSAEK subjects with clear grafts at 12 months, 107 (80%) had analyzable specular images, 4 (3%) had clear grafts but the 12-month postoperative image was not analyzable, and the remaining 23 (17%) had clear grafts but no image was obtained.
Sixty-four eyes were treated with a 5.0-mm incision width and 103 eyes with a 3.2-mm incision width. Comparable percentages of eyes in each group had analyzable 12-month specular images obtained (70% vs 60%, respectively; P = 0.072).
Donor and Recipient Characteristics
Donor characteristics are summarized in Table 1 . The mean baseline ECD was comparable for the 2 sites (P = 0.97). The 3.2-mm incision group had a mean death-to-preservation time 1.3 hours longer (P = 0.0034), and a mean deathto-surgery time 0.6 days shorter (P = 0.0056), and the mean donor age was 5 years older (P = 0.036). The mean graft diameter was comparable for the 2 sites (8.9 vs 8.8 mm, P = 0.30).
Recipient characteristics are summarized in Table 2 . The 2 sites had comparable proportions of males and females (P = 0.82), comparable preoperative diagnoses (P = 0.47), and comparable postoperative lens status (P = 0.45). In the 5-mm incision group, the mean recipient age was 5 years younger (P = 0.021), the racial distribution was slightly more diverse (P = 0.045), and about one-third of the subjects were phakic before undergoing DSAEK (P , 0.001).
Graft Success
The regraft rate was comparable for the 2 sites (P = 1.0). None of the grafts experienced primary failure. Within the 5-mm incision group, 1 eye (1.6%) was regrafted to treat visually significant wrinkles in the graft. Within the 3.2-mm incision group, 3 eyes (2.9%) were regrafted, 1 to treat visually significant wrinkles in the graft, 1 because of unsatisfactory vision that was subsequently determined to be related to stromal haze in the recipient cornea, and 1 to treat graft decompensation caused by immunologic rejection.
Complications
The rate of postoperative complications was comparable at the 2 sites. Among the treated eyes in the 5-and 3.2-mm incision groups, respectively, intraocular pressure spikes exceeding 25 mm Hg occurred in 20% versus 14% (P = 0.28), immunologic graft rejection episodes occurred in 8% versus 4% (P = 0.31), and graft dislocation and rebubbling occurred in 3% versus 8% (P = 0.32). No eyes in either group experienced pupillary block glaucoma.
Endothelial Cell Loss
Compared with the 3.2-mm incision width cohort, the 5.0-mm incision width cohort experienced significantly lower endothelial cell loss at 6 months [27% 6 20% (range 23% gain to 67% loss) vs 40% 6 22% (range 1%-81% loss)] and at 12 months [31% 6 19% (range 25% gain to 70% loss) vs 44% 6 22% (range 4% gain to 80% loss), both P , 0.001] ( Table 3 ). Endothelial cell loss did not increase by a statistically significant amount between 6 and 12 months in either cohort (P = 0.35 and P = 0.25, respectively).
DISCUSSION
The key finding in this study was that compared with insertion through a 3.2-mm-wide incision, DSAEK graft insertion through a 5.0-mm-wide incision resulted in significantly lower 6-and 12-month endothelial cell loss. Identifying such a simple technique variation that can reduce endothelial cell loss after the first year of this procedure is particularly important because endothelial decompensation is a leading cause of graft failure after standard PKP and endothelial cell loss during this period is significantly higher with DSAEK. 2,5,11 These 6-and 12-month results confirm for the first time in a clinical study of DSAEK predictions of significantly lower cell loss with a 5.0-mm incision width, compared with a 3.0-mm width using single-point fixation forceps, based on a laboratory model by Terry et al. 4 Folding the graft through a smaller incision width likely causes more tissue compression and associated endothelial cell damage. Our findings are consistent with observations of increased 1-year cell loss with a smaller incision width (5 vs 9 mm) for posterior lamellar keratoplasty and deep lamellar endothelial keratoplasty procedures. 12, 13 Despite the significant difference in endothelial cell loss, 1-year graft survival was comparable for the 2 incision widths. Importantly, no primary graft failures occurred in either group. However, additional follow-up is required to evaluate long-term graft survival rates.
The results of this study are specifically applicable to cases in which the graft is folded approximately in half, then grasped, and inserted with single-point fixation forceps. Other methods of graft insertion include the suture pull-through method or pulling the graft into the anterior chamber through or over a glide. [14] [15] [16] Recently, several different injector designs have been introduced to curl the graft and protect it from compressive forces as it goes through the incision; however, there are no comparative studies examining endothelial cell loss with these new injector designs, which are a more expensive option as single-use instruments.
This study had several limitations. The ideal study design would be a prospective trial randomizing on the basis of wound size and all other donor, recipient, and operative parameters as the same. In this study, the DSAEK group was enrolled prospectively for a comparative study with a subset of PKP patients in the SMAS of the CDS, sharing similar donor and recipient criteria without regard to specifying all operative parameters in the DSAEK procedure for the 2 surgeons. 4 Any operative differences and their impact on graft survival and endothelial cell loss were not known at the outset of the study. This data set thus afforded the opportunity to perform a retrospective analysis of the major difference between the 2 surgical techniques, wound size. However, the investigators were not masked to wound size, eyes were not randomized on this basis, and a number of minor donor, recipient, and operative differences between the 2 groups that could have confounded the results arose. These differences included in the 5.0-mm incision group a mean donor death-to-preservation time 1.3 hours shorter, mean donor death-to-use time 0.6 days longer, mean donor and recipient ages 5 years younger, use of balanced salt solution rather than air to pressurize the artificial anterior chamber used for donor dissection, and a shorter complete air fill (8 vs 60 minutes). Also, 25% of the DSAEK cases were combined with cataract extraction and intraocular lens implantation in the 5.0-mm incision group, whereas no triple procedures were performed in the 3.2-mm incision group.
However, previous studies suggest that these minor differences were unlikely to have had a significant effect on the outcomes. A study of 263 Descemet stripping endothelial keratoplasty eyes showed that donor death-to-preservation time, donor death-to-use time, and recipient age were not significantly associated with 6-month endothelial cell loss. 17 Although donor age was weakly correlated with 6-month cell loss in that earlier study, donor age and ECD were confounded. 17 That earlier study also showed that clear corneal incisions were associated with lower cell loss than scleral tunnel incisions. In the current study, the 5.0-mm incision group included some scleral tunnel incisions, whereas the 3.2-mm incision group did not. So differences in incision construction would not account for the lower cell loss seen in the 5.0-mm incision group. 17 To our knowledge, no studies have compared the duration of full air fill with endothelial cell loss. Finally, endothelial cell loss has been shown to be comparable for eyes undergoing triple versus single procedures. 18 Most importantly, in the current study, baseline donor ECD was virtually identical for the 2 sites and recipient diagnosis was the same, an important risk factor for graft failure noted in the CDS. 6 Despite these limitations, given the significant and greater than 10% difference in endothelial cell loss between the groups at both 6-and 12-month postoperative time points, we feel confident that the use of a 5.0-mm incision width is associated with significantly lower 6-and 12-month endothelial cell loss than the use of a smaller 3.2-mm incision width for forceps insertion of folded DSAEK grafts. Despite this difference in cell loss, the early 1-year graft survival rates were comparable, and thus, additional follow-up is needed to determine whether the larger incision has an advantage over the smaller incision in terms of long-term graft survival. 
